LUMO
Income statement / Annual
Last year (2023), Lumos Pharma, Inc.'s total revenue was $2.05 M,
an increase of 34.67% from the previous year.
In 2023, Lumos Pharma, Inc.'s net income was -$34.03 M.
See Lumos Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.05 M |
$1.52 M |
$230,000.00 |
$168,000.00 |
$936,000.00 |
$1.21 M |
$390,000.00 |
$3.53 M |
$36.14 M |
$165.95 M |
| Cost of Revenue |
$0.00
|
$49,000.00
|
$0.00
|
$0.00
|
$37,000.00
|
-$11.27 M
|
$1.41 M
|
$0.00
|
-$32.36 M
|
-$6.64 M
|
| Gross Profit |
$2.05 M
|
$1.47 M
|
$230,000.00
|
$168,000.00
|
$899,000.00
|
$12.47 M
|
-$1.02 M
|
$3.53 M
|
$68.50 M
|
$172.59 M
|
| Gross Profit Ratio |
1
|
0.97
|
1
|
1
|
0.96
|
10.34
|
-2.61
|
1
|
1.9
|
1.04
|
| Research and Development Expenses |
$22.10 M
|
$17.86 M
|
$16.25 M
|
$9.21 M
|
$22.21 M
|
$45.69 M
|
$69.87 M
|
$93.30 M
|
$71.41 M
|
$35.69 M
|
| General & Administrative Expenses |
$16.57 M
|
$15.71 M
|
$15.33 M
|
$17.27 M
|
$23.87 M
|
$29.22 M
|
$31.73 M
|
$33.23 M
|
$30.69 M
|
$19.33 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.57 M
|
$15.71 M
|
$15.33 M
|
$17.27 M
|
$23.87 M
|
$29.22 M
|
$31.73 M
|
$33.23 M
|
$30.69 M
|
$19.33 M
|
| Other Expenses |
$0.00
|
$91,000.00
|
$269,000.00
|
$6.47 M
|
-$19,000.00
|
-$102,000.00
|
$371,000.00
|
$247,000.00
|
-$41,000.00
|
$60,000.00
|
| Operating Expenses |
$38.67 M
|
$33.56 M
|
$31.58 M
|
$26.47 M
|
$46.07 M
|
$63.64 M
|
$73.27 M
|
$94.28 M
|
$69.75 M
|
$48.38 M
|
| Cost And Expenses |
$38.67 M
|
$33.56 M
|
$31.58 M
|
$26.47 M
|
$46.07 M
|
$63.64 M
|
$73.27 M
|
$94.28 M
|
$69.75 M
|
$48.38 M
|
| Interest Income |
$1.87 M
|
$874,000.00
|
$12,000.00
|
$200,000.00
|
$2.23 M
|
$2.03 M
|
$616,000.00
|
$237,000.00
|
$78,000.00
|
$86,000.00
|
| Interest Expense |
$0.00
|
$874,000.00
|
$0.00
|
$0.00
|
$50,000.00
|
$52,000.00
|
$119,000.00
|
$22,000.00
|
$105,000.00
|
$26,000.00
|
| Depreciation & Amortization |
$44,000.00
|
$49,000.00
|
$273,000.00
|
$584,000.00
|
$37,000.00
|
$1.15 M
|
$1.41 M
|
$2.08 M
|
$1.59 M
|
$1.10 M
|
| EBITDA |
-$36.57 M |
-$31.99 M |
-$31.13 M |
-$25.72 M |
-$45.13 M |
-$59.37 M |
-$70.98 M |
-$88.41 M |
-$31.95 M |
$118.76 M |
| EBITDA Ratio |
-17.83
|
-21.04
|
-136.29
|
-156.57
|
-45.86
|
-50.17
|
-186.87
|
-25.74
|
-0.93
|
0.71
|
| Operating Income Ratio |
-17.85
|
-21.04
|
-136.29
|
-156.57
|
-48.22
|
-51.77
|
-186.87
|
-25.74
|
-0.93
|
0.71
|
| Total Other Income/Expenses Net |
$2.55 M
|
$965,000.00
|
$281,000.00
|
$6.67 M
|
$35.43 M
|
$1.88 M
|
$371,000.00
|
$247,000.00
|
-$41,000.00
|
$60,000.00
|
| Income Before Tax |
-$34.06 M
|
-$31.08 M
|
-$31.07 M
|
-$19.64 M
|
-$42.98 M
|
-$60.56 M
|
-$72.51 M
|
-$90.51 M
|
-$33.64 M
|
$117.63 M
|
| Income Before Tax Ratio |
-16.61
|
-20.4
|
-135.07
|
-116.88
|
-45.92
|
-50.22
|
-185.92
|
-25.67
|
-0.93
|
0.71
|
| Income Tax Expense |
-$29,000.00
|
-$13,000.00
|
-$636,000.00
|
-$13.97 M
|
$12,000.00
|
-$6.97 M
|
-$559,000.00
|
-$5.36 M
|
$6.74 M
|
$14.78 M
|
| Net Income |
-$34.03 M
|
-$31.06 M
|
-$30.43 M
|
-$5.66 M
|
-$42.99 M
|
-$53.60 M
|
-$71.95 M
|
-$85.16 M
|
-$40.38 M
|
$102.86 M
|
| Net Income Ratio |
-16.59
|
-20.4
|
-132.3
|
-33.71
|
-45.93
|
-44.44
|
-184.49
|
-24.15
|
-1.12
|
0.62
|
| EPS |
-4.18 |
-3.71 |
-3.65 |
-0.84 |
-297.07 |
-12.97 |
-20.69 |
-26.45 |
-12.71 |
31.05 |
| EPS Diluted |
-4.18 |
-3.71 |
-3.65 |
-0.84 |
-297.07 |
-12.97 |
-20.69 |
-26.45 |
-12.71 |
27.81 |
| Weighted Average Shares Out |
$8.15 M
|
$8.37 M
|
$8.33 M
|
$6.78 M
|
$144,709.00
|
$4.13 M
|
$3.48 M
|
$3.22 M
|
$3.18 M
|
$3.09 M
|
| Weighted Average Shares Out Diluted |
$8.15 M
|
$8.37 M
|
$8.33 M
|
$6.78 M
|
$144,709.00
|
$4.13 M
|
$3.48 M
|
$3.22 M
|
$3.18 M
|
$3.45 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
